WO2023213779 - NOVEL ANTI-ANGPTL3 ANTIBODIES SUITABLE FOR HIGH CONCENTRATION COMPOSITIONS AND SUBCUTANEOUS ADMINISTRATION
National phase entry:
Publication Number
WO/2023/213779
Publication Date
09.11.2023
International Application No.
PCT/EP2023/061478
International Filing Date
02.05.2023
Title **
[English]
NOVEL ANTI-ANGPTL3 ANTIBODIES SUITABLE FOR HIGH CONCENTRATION COMPOSITIONS AND SUBCUTANEOUS ADMINISTRATION
[French]
NOUVEAUX ANTICORPS ANTI-ANGPTL3 APPROPRIÉS POUR DES COMPOSITIONS À CONCENTRATION ÉLEVÉE ET ADMINISTRATION SOUS-CUTANÉE
Applicants **
NOVO NORDISK A/S
Novo Allé
2880 Bagsværd, DK
Inventors
HENRIKSEN, Anette
Novo Alle 1
2880 Bagsværd, DK
KROGH, Thomas Nylandsted
Novo Alle 1
2880 Bagsværd, DK
GREISEN, Per j.
Novo Alle 1
2880 Bagsværd, DK
EGEBJERG, Thomas
Novo Alle 1
2880 Bagsværd, DK
Priority Data
22171090.8
02.05.2022
EP
22201248.6
13.10.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1661 | |
| EPO | Filing, Examination | 6797 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 606 | |
| USA | Filing, Examination | 3910 |
Total: 13561 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to novel monovalent anti-ANGPTL3 antibodies for use in medicine and in particular for lowering of plasma triglycerides levels in patients in need thereof, such as patients suffering from or at risk of hypertriglyceridemia and/or cardiovascular disease, such as atherosclerotic cardiovascular disease (ASCVD) as well as pharmaceutical compositions suitable for subcutaneous administration and kits comprising such compounds and compositions.[French]
La présente invention concerne de nouveaux anticorps anti-ANGPTL3 monovalents destinés à être utilisés en médecine et en particulier pour abaisser les taux de triglycérides plasmatiques chez des patients qui en ont besoin, tels que des patients atteints ou à risque d'hypertriglycéridémie et/ou de maladie cardiovasculaire, tels que la maladie cardiovasculaire athérosclérotique (ASCVD) ainsi que des compositions pharmaceutiques appropriées pour une administration sous-cutanée et des kits comprenant de tels composés et compositions.